The differences in progression-free survival (PFS) and cancer-specific survival (CSS) of metastatic renal cell carcinoma (mRCC) patients according to treatment, type of metastasis, and Heng criteria risk are unclear. In this study, we compared survival according to various such parameters. | Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma A retrospective analysis